Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI(3)kinase/AKT/Bcl-X(L) Activation and CD8(+) T Cell–mediated Tumor Eradication

Por Zhong, Xiao-Song, Matsushita, Maiko, Plotkin, Jason, Riviere, Isabelle, Sadelain, Michel
Publicado em 2009

Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition

Por Condomines, Maud, Arnason, Jon, Benjamin, Reuben, Gunset, Gertrude, Plotkin, Jason, Sadelain, Michel
Publicado no PLoS One (2015)

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity

Por Adusumilli, Prasad S., Cherkassky, Leonid, Villena-Vargas, Jonathan, Colovos, Christos, Servais, Elliot, Plotkin, Jason, Jones, David R., Sadelain, Michel
Publicado no Sci Transl Med (2014)

Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells

Por Zhao, Zeguo, Condomines, Maud, van der Stegen, Sjoukje J.C., Perna, Fabiana, Kloss, Christopher C., Gunset, Gertrude, Plotkin, Jason, Sadelain, Michel
Publicado no Cancer Cell (2015)